Glenmark Pharmaceuticals Limited (GLENMARK) Net Income 2022–2026

Name: Glenmark Pharmaceuticals Limited (GLENMARK) net income history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Glenmark Pharmaceuticals Limited annual net income for fiscal 2026 was ₹13.6 billion, an increase of 30.1% from ₹10.5 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

GLENMARK Annual Net Income

Net Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Net Income	₹13.6B	₹10.5B	(₹15.0B)	₹3.0B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GLENMARK Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Net Income	₹4.8B	₹3.0B	₹4.0B	₹6.1B	₹469M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

DRREDDY Net Income — Dr. Reddy's Laboratories Limited
LUPIN Net Income — Lupin Limited
MANKIND Net Income — Mankind Pharma Limited
4506 Net Income — Sumitomo Pharma Co., Ltd.
ALKEM Net Income — Alkem Laboratories Limited
ABBOTINDIA Net Income — Abbott India Limited

More GLENMARK metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All GLENMARK financial statements → Interactive GLENMARK charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.